Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

HELIOS-B

- PMLiVE

Alnylam’s Amvuttra approved by MHRA to treat rare heart disease ATTR-CM

The drug has been authorised to treat both wild-type and hereditary forms of the disease

- PMLiVE

Alnylam’s Amvuttra granted EC approval to treat rare heart disease ATTR-CM

The RNAi therapeutic has been authorised to treat both wild type and hereditary forms of the disease

- PMLiVE

Alnylam shares phase 3 results for Amvuttra in rare heart disease ATTR-CM

Transthyretin amyloid cardiomyopathy is estimated to affect over 300,000 people worldwide

- PMLiVE

Alnylam’s RNAi therapeutic vutrisiran recommended by CHMP for rare heart disease

The committee has recommended the drug for both wild type and hereditary ATTR-CM

- PMLiVE

Alnylam’s Amvuttra granted FDA approval for rare heart disease ATTR-CM

Approximately 150,000 people in the US are affected by transthyretin amyloid cardiomyopathy

- PMLiVE

Alnylam shares positive phase 3 results for vutrisiran in ATTR with cardiomyopathy

The company said it will be proceeding with regulatory filings for the therapy later this year

- PMLiVE

Alnylam presents positive late-stage results for RNAi therapeutic in ATTR with cardiomyopathy

Hereditary ATTR and wild-type ATTR are responsible for an estimated 350,000 cases globally

- PMLiVE

Alnylam’s patisiran backed by FDA advisory committee for ATTR cardiomyopathy

Treatment options for the underdiagnosed and rapidly progressive condition are currently limited

- PMLiVE

Roche partners with Alnylam on hypertension therapy in deal worth up to $2.8bn

Zilebesiran is in phase 2 development to treat hypertension in patients with high-unmet needs

- PMLiVE

Alnylam presents promising results for RNAi therapeutic in Alzheimer’s disease at AAIC

ALN-APP is the first investigational RNAi therapeutic to show gene silencing in the human brain

- PMLiVE

Alnylam’s RNAi therapeutic recommended by NICE for hereditary form of amyloidosis

Amvuttra is given every three months, compared to every few weeks with existing therapies

- PMLiVE

Alnylam’s RNAi therapeutic expanded by FDA in advanced primary hyperoxaluria type 1

A phase 3 trial showed Oxlumo treatment resulted in substantial reductions in plasma oxalate

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links